Pediatric small round blue cell tumors (SRBCTs) are a heterogeneous group of neoplasms with overlapping morphological appearance. Accordingly, their diagnosis is one of the most difficult in the field of surgical pathology. The most common tumors include rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, lymphoblastic lymphoma and Wilms' tumor (the blastemal component). Over time their diagnosis has become more difficult due to the increasing use of small biopsies. However, the advent of immunohistochemistry has improved the quality of diagnosis in most cases by the application of an adequate panel of immunomarkers. Recently, WT1 and Cyclin D1 have been shown to be useful in the differential diagnosis of SRBCTs on surgically-resected specimens, showing a diffuse cytoplasmic positivity of the former in all RMSs and a diffuse nuclear staining of the latter in both EWS and NB. The aim of the present study was to investigate the expression of WT1 and Cyclin D1 on small biopsies from a series of 105 pediatric SRBCTs to evaluate their diagnostic utility. Both immunomarkers were differentially expressed, with a diffuse and strong cytoplasmic staining for WT1 limited to all cases of RMS, and a diffuse nuclear staining for cyclin D1 restricted to all cases of EWS and NB. Notably, the expression of WT1 and cyclin D1 was also retained in those cases in which the conventional tumor markers (myogenin, desmin and MyoD1 for RMS; CD99 for EWS; NB84 for NB) were focally expressed or more rarely absent. The present study shows that WT1 and Cyclin D1 are helpful immunomarkers exploitable in the differential diagnosis of pediatric SRBCTs on small biopsies, suggesting their applicability in routine practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700162PMC
http://dx.doi.org/10.3390/diagnostics11122254DOI Listing

Publication Analysis

Top Keywords

wt1 cyclin
20
small biopsies
16
diagnosis pediatric
8
pediatric small
8
small round
8
round blue
8
blue cell
8
cell tumors
8
diagnosis difficult
8
differential diagnosis
8

Similar Publications

Article Synopsis
  • There is a significant challenge in diagnosing ovarian high-grade endometrioid carcinoma (HGEC) and high-grade serous carcinoma (HGSC) due to their similar histopathological features, leading to variability among observers.
  • A study analyzed a variety of ovarian cancer samples using advanced sequencing and clustering techniques, identifying four distinct tumor groups with different characteristics and survival outcomes.
  • The findings suggest that a specific subset of tumors, termed "HGEC-type," shows favorable prognosis and endometrial differentiation, which may often be misclassified as HGSCs, indicating a need for improved diagnostic strategies.
View Article and Find Full Text PDF

EWS fusion oncoproteins underlie several human malignancies including Desmoplastic Small Round Cell Tumor (DSRCT), an aggressive cancer driven by EWS-WT1 fusion proteins. Here we combine chromatin occupancy and 3D profiles to identify EWS-WT1-dependent gene regulation networks and target genes. We show that EWS-WT1 is a powerful chromatin activator controlling an oncogenic gene expression program that characterizes primary tumors.

View Article and Find Full Text PDF

Background: Rhabdomyosarcomas are aggressive tumors that comprise a group of morphologically similar but biologically diverse lesions. Owing to its rarity, Mixed pattern RMS (ARMS and ERMS) constitutes a diagnostic and therapeutic dilemma.

Case: Herein is presented a very rare case of mixed alveolar & embryonal rhabdomyosarcoma in the uterus of a 68-year-old woman.

View Article and Find Full Text PDF
Article Synopsis
  • Desmoplastic small round cell tumors (DSRCT) are aggressive pediatric sarcomas linked to the EWSR1::WT1 fusion oncogene, with poor survival rates of 15% to 25% due to ineffective standard treatments.
  • The study demonstrated that targeting EWSR1::WT1 is crucial for DSRCT growth and identified its unique role in activating genes related to the cyclin D-CDK4/6-RB pathway.
  • Treatment with the FDA-approved CDK4/6 inhibitor palbociclib effectively reduced DSRCT growth in models, suggesting a promising new therapeutic option for this challenging cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!